Aravive Inc. (ARAV) Announces Dose Escalation in Phase 1b Trial of Cancer Drug AVB-500
Tweet Send to a Friend
Aravive, Inc. (Aravive) (NASDAQ: ARAV) today announced that the independent Data Monitoring Committtee (DMC) has reviewed the open-label data following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE